C

디티앤씨알오

383930KOSDAQ

50.8 / 100

Reference Date: 2026-09-08

Financial Score20.5 / 40
News Sentiment16.3 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Plunged 17.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

DT&CR is a Full-Service CRO providing non-clinical and clinical trial services across pharmaceuticals, medical devices, and health functional foods, offering integrated solutions from early-stage drug development to FDA approval. In 2025, revenue increased by 32.7% year-over-year to 47.7 billion won, driven by specialized services such as the expanded PK/PD center, which scientifically analyzes drug candidate characteristics.

Number of Employees

314people

Average Salary

47.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 15.004.0Point
PBR
0.78Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
-10.33Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
54.18Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲34.0% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲28.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -19.9% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 1Average Sentiment Score 65

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 1,527Won52-week high 3,74552-week low 1,450
1-month return0.0Point

1m -17.01% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral신주인수권행사가액의조정2026-08-20
  • Neutral전환가액의조정2026-08-20
  • Neutral[기재정정]전환가액의조정2026-08-20
  • Neutral신주인수권행사가액의조정2026-08-20
  • Neutral반기보고서 (2026.06)2026-08-14